Asset profile

ribupatide

Peptide

Phase 3underway

Evidence outlook · registrational

Atherosclerotic Cardiovascular Disease: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2031-05.

Also in development:Type 2 Diabetes · Phase 3Obesity · Phase 3Heart Failure · Phase 2

How the evidence outlook works ↗

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (2)
December 2026 (2)
Phase 3ObesityRecruiting
Est. primary completion 2026-12 · NCT06994650 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3ObesityRecruiting
Est. primary completion 2026-12 · NCT06974851 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (5)
February 2027 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2027-02 · NCT07060456 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)
Phase 3ObesityActive not recruiting
Est. primary completion 2027-03 · NCT07285902 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)
Phase 2ObesityActive not recruiting
Est. primary completion 2027-05 · NCT07458269 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Type 2 DiabetesRecruiting
Est. primary completion 2027-05 · NCT07599410 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)
Phase 3Chronic Management of Body WeightRecruiting
Est. primary completion 2027-10-31 · NCT07670884 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (4)
February 2028 (1)
Phase 3ObesityRecruiting
Est. primary completion 2028-02 · NCT07284875 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (2)
Phase 3ObesityRecruiting
Est. primary completion 2028-03 · NCT07284979 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3ObesityRecruiting
Est. primary completion 2028-03-27 · NCT07284901 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (1)
Phase 3ObesityNot yet recruiting
Est. primary completion 2028-11 · NCT07709910 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)
May 2031 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2031-05 · NCT07551492 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.